0000000000084408

AUTHOR

Salvatore Crisafulli

showing 2 related works from this author

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct

COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy

2021

Evidence on treatments for early-stage COVID-19 in outpatient setting is sparse. We explored the pattern of use of drugs prescribed for COVID-19 outpatients’ management in Southern Italy in the period February 2020–January 2021. This population-based cohort study was conducted using COVID-19 surveillance registry from Caserta Local Health Unit, which was linked to claims databases from the same catchment area. The date of SARS-CoV-2 infection diagnosis was the index date (ID). We evaluated demographic and clinical characteristics of the study drug users and the pattern of use of drugs prescribed for outpatient COVID-19 management. Overall, 40,030 patients were included in the analyses, with…

ItalyRCOVID-19; Italy; outpatientsCOVID-19MedicineCOVID-19; outpatients; ItalyGeneral MedicineOutpatients.ArticleoutpatientsJournal of Clinical Medicine
researchProduct